Effects of PCSK9 inhibition on glucose metabolism and β-cell function in humans: a pilot study

BACKGROUND: Anti-PCSK9 monoclonal antibodies are effective in reducing LDL-C and cardiovascular events by neutralizing circulating PCSK9. PCSK9, however, is also expressed in tissues, including the pancreas, and studies on PCSK9 KO mice have shown impaired insulin secretion. Statin treatment is alre...

Descripción completa

Detalles Bibliográficos
Autores principales: Moffa, Simona, Mezza, Teresa, Ferraro, Pietro Manuel, Di Giuseppe, Gianfranco, Cefalo, Chiara M. A., Cinti, Francesca, Impronta, Flavia, Capece, Umberto, Ciccarelli, Gea, Mari, Andrea, Pontecorvi, Alfredo, Giaccari, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266211/
https://www.ncbi.nlm.nih.gov/pubmed/37324254
http://dx.doi.org/10.3389/fendo.2023.1124116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10266211/
https://www.ncbi.nlm.nih.gov/pubmed/37324254
http://dx.doi.org/10.3389/fendo.2023.1124116

Ejemplares similares